Last reviewed · How we verify

brimonidine 0.1% (Alphagan® P) — Competitive Intelligence Brief

brimonidine 0.1% (Alphagan® P) (brimonidine 0.1% (Alphagan® P)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Ophthalmology.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

brimonidine 0.1% (Alphagan® P) (brimonidine 0.1% (Alphagan® P)) — Allergan. Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
brimonidine 0.1% (Alphagan® P) TARGET brimonidine 0.1% (Alphagan® P) Allergan marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Normal saline, Lidocaine, dexmetomidine Normal saline, Lidocaine, dexmetomidine Kasr El Aini Hospital marketed Local anesthetic combination with sedative-analgesic agent Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Venlafaxine XR + Mirtazapine Venlafaxine XR + Mirtazapine National Institute of Mental Health (NIMH) marketed Antidepressant combination (SNRI + NaSSA) Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Dexmedetomidine 0.75 microgram/kg Dexmedetomidine 0.75 microgram/kg Sindh Institute of Urology and Transplantation marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Group D : Dexmedetomidine + propofol group Group D : Dexmedetomidine + propofol group Seoul National University Hospital marketed Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist) Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Dexmedetomidine (DEX) Dexmedetomidine (DEX) Ain Shams University marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Dexmedetomidine 0.5 microgram/kg Dexmedetomidine 0.5 microgram/kg Sindh Institute of Urology and Transplantation marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

  1. Allergan · 3 drugs in this class
  2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
  3. National Cancer Institute, Egypt · 2 drugs in this class
  4. The University of Hong Kong · 2 drugs in this class
  5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
  6. Fayoum University Hospital · 1 drug in this class
  7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
  8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
  9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  10. KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). brimonidine 0.1% (Alphagan® P) — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-0-1-alphagan-p. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: